Pfizer Names Andrew Baum Chief Strategy, Innovation Officer
By Colin Kellaher
Pfizer had hired Andrew Baum as the drugmaker's next chief strategy and innovation officer.
Pfizer on Monday said Baum, who has been Citi's head of global healthcare and managing director of equity research, joins the New York company as an executive vice president and a member of its executive leadership team, reporting to chairman and chief executive Albert Bourla.
Baum succeeds Aamir Malik, who recently became executive vice president and chief U.S. commercial officer.
Pfizer said Baum, who takes up his new post on June 3, will be responsible for portfolio analysis and prioritization functions and also will serve as chairman of its portfolio-management team, the company's most senior governing body responsible for portfolio management and capital deployment across its research-and-development pipeline.
Baum, who joined Citi in 2011 after covering European pharmaceuticals at Morgan Stanley for 14 years, was a practicing physician earlier in his career, Pfizer said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 06, 2024 07:21 ET (11:21 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing